Top-line GrowthSustained revenue expansion culminating in a ~32% surge in 2026 indicates strong consumer demand and effective store/merchandising execution. Durable top-line momentum supports capacity to invest in network, procurement scale, and long-term profitability if margin pressures are addressed.
Stable Gross MarginsConsistent ~30% gross margins over multiple years point to resilient product mix and procurement/distribution economics in a retail pharmacy model. Stable gross margins create a reliable base for operating leverage as sales scale, supporting medium-term margin recovery and reinvestment capacity.
Improving Cash Generation (2026)A material uptick in operating and free cash flow in 2026 signals renewed ability to self-fund capex, pay down obligations, or support dividends. While prior volatility exists, stronger cash conversion of recent year enhances near-term financial flexibility and funds strategic initiatives.